WATERTOWN, Mass., Oct. 11, 2016 -- A new study shows pediatricians ranked temporal artery thermometry (TAT) number one in overall preference over any other thermometry method and furthermore use and recommend the Exergen TemporalScanner over any other brand including Welch Allyn. Forty two percent of pediatricians use the Exergen TAT and 36 percent recommend it to their patients, ranking highest in both categories, compared to the Welch Allyn Electronic Rectal/Oral/Axillary thermometers, ranking second and third respectively. In addition, the results show that nearly two-thirds of pediatricians (64.4 percent) who use or recommend Exergen temporal artery thermometers do so for patients of all ages, also the highest of any thermometer brand.
Of the 268 survey respondents, 40.5 percent ranked TAT number one based on overall preference, compared to 17.7% for rectal, 27.2% for ear, 10.3% for oral and 3.9% for axillary thermometry. In addition, more than half (57.3 percent) of pediatricians ranked TAT number one in ease of use.
“These study results are a powerful testament that the Exergen Temporal Thermometer sets the gold standard for pediatricians,” said Dr. Francesco Pompei, CEO of Exergen Corporation. “With more than 60 clinical studies supporting its accuracy, physicians have come to trust and rely on the Exergen TemporalScanner over all other brands. It is non-invasive, easy to use and accurate, which enhances the physician-patient bond."
Survey respondents noted strengths of temporal artery thermometry, including ease of use and accuracy. The survey also captured pediatricians' commentary about temporal artery thermometry. According to one physician respondent, "Temporal Artery Exergen has made my life very easy!" Another respondent said, “Temporal Artery is easy to use for nurse, patient and family.”
The survey was conducted by Pragmatic Research, Inc. and pediatricians were not told that it was sponsored by Exergen. The results were consistent with other independent research involving nurses and other healthcare professionals in various clinical settings.
ABOUT EXERGEN CORPORATION
Exergen Corporation is a recognized world leader in industrial and medical non-invasive temperature technology. The company manufactures and markets TemporalScanner thermometer models for hospitals and clinics, and a consumer model sold in major retailers nationwide. Nearly two billion temperatures are taken each year with Exergen TemporalScanners in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, nurses, and mothers and is the #1 selling retail thermometer. The Exergen TemporalScanner’s performance is supported by more than 60 peer-reviewed published studies covering all ages from preterm infants to geriatrics, and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
Contact: Victoria Day Rosica Public Relations [email protected] P: 201.843.5600 F: 201.843.5680 21-00 Route 208 South, Suite 130 Fair Lawn, NJ 07410


U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Britain Courts Anthropic Amid US Defense Department Dispute
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 



